



An International Specialty Pharmaceutical Group

November 2021

Recordati Today – Summary Overview

Business Overview

International specialty pharmaceutical group:

- Well diversified footprint
- Strong vertical integration

Specialty and Primary Care Division (78% sales):

- **Prescription products:** well-established, branded portfolio of prescription drugs focused on core therapeutic areas across cardiovascular, urology, gastrointestinal and central nervous system (**57% sales**)
- **OTC:** marketing of branded OTC products primarily in Europe (**18% sales**)
- **Chemicals:** production of active pharmaceutical ingredients (“API”) sold to third party pharmaceutical companies (**3% sales**)
- Direct operations in all European markets, in Russia and C.I.S., Turkey and North Africa

Rare Diseases Division (22% sales):

- Treatments for rare diseases, particularly **metabolic** deficiencies and rare **endocrine** conditions of a genetic origin
- Active product development pipeline
- Worldwide business (US, EMEA and RoW)

8 manufacturing facilities (of which 2 API production sites) and a specialised packaging and distribution facility dedicated to rare diseases

- **Pharma Production** in Italy, Turkey, France, Tunisia, Spain, and Czech Republic
- **API Manufacturing** in Ireland and Italy

Recordati Snapshot – FY 2020

€1.45bn
Net
Revenue

€569m
EBITDA⁽¹⁾

€355m
Net Income

~150
Markets

> 4,300
Employees


Specialty & Primary Care

- €1,129.5m Revenue
- EBITDA margin 37.3%
- EBIT margin 30.9%


Rare Disease

- €319.4m Revenue
- EBITDA margin 46.4%
- EBIT margin 37.5%

By Geography ⁽²⁾



By Therapeutic Area ⁽²⁾



(1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items. (2) Breakdown based on pharmaceutical sales; * Endo 2020 includes direct Recordati sales only (net margin transfer from Novartis excluded)

A proven and sustainable Business Model...

Well Diversified Revenue Base

- Very broad portfolio and diversified footprint minimizes exposure to single product/ market combination
- Limited exposure to single reimbursement systems

Pursue Accretive and Growth Deals

- Strong M&A track record of product and corporate acquisitions as well as licensing to complement portfolio
- Disciplined approach, with focus on long term value creation (mix of growth and accretive deals)

Minimize development risk

- Selective R&D investments with majority of net revenue coming from mature products and products sourced externally via licensing and BD

Focus on Volume-Led Growth


- Organic growth primarily fueled by volume-driven growth rather than price
- Good exposure to markets with positive growth outlook (Turkey, Russia, North Africa)

Carefully manage LOEs

- Proven successful strategy of stabilising key products post LOE, through active promotion
- No major LOE exposure over the next 5 years

Control Supply


- Fully vertical integrated platform from API to sale for key products, driving margin and protecting the supply chain
- c.60% of volumes manufactured by Recordati plants



...that has delivered consistent growth and margin improvement

Sales and profitability driven by organic growth and successful BD

(million Euro)



Company Strategy

Group Objectives

Continuation of successful strategy
Steady organic growth from well diversified portfolio
Enhanced by accretive or strategic acquisitions in both SPC & Rare Diseases

Specialty & Primary Care

- Preserve the value of established brands with steady volume-led organic growth from core products
- Reinforce current geographical footprint to remain a partner of choice
- Leverage additional new products on the current organisation
- Reinvest cash flow in accretive acquisitions

Enablers

- High SoV in key Primary and Specialty Care markets
- Locally empowered know-how
- Omnichannel approach

Capabilities

- ~1,900 sales FTEs in 30+ countries
- Fully integrated Pharma Co
- Proven track record of acquisitions integration

Rare Diseases

- Continue developing the existing portfolio of global brands
- Consolidation of Latin American and Asia/Pacific presence
- Drive growth of recent launches - Signifor®, Signifor® LAR, Isturisa®, Cystadrops®, Ledaga® & Juxtapid®
- Progress current R&D pipeline
- Invest in targeted BD and M&A to reinforce global portfolio

Enablers

- 80+ new hires on board to support Endo franchise
- Numerous patient advocacy partnerships
- Global branding

Capabilities

- Direct presence in US, Europe and Asia
- Patient access
- Disease awareness programs

Exposure to Positive Macro Trends

Aging populations fuelling higher healthcare expenditure and greater prevalence of chronic disease

Recordati portfolio weighted towards age-related diseases: cardiology, urology, gastrointestinal...

Emerging market exposure driving long term local currency growth: Turkey, Russia, CEE and CIS

Significant unmet need remaining in Rare Diseases, with c.500 approved drugs to date vs. > 7,000 designated rare diseases

A commitment to a sustainable future

Patient Care

- Continue to develop and offer **innovative products** that improve **quality of life**
- Maintaining the **highest product quality and safety standards** throughout the product life cycle
- Constant focus on **improving access to medical products** and health care: patient-centric approach, including the most vulnerable categories (rare diseases)

People Care

- Have an **inclusive culture** and **promote equal opportunities**
- Protect the **health and safety** of our employees
- **Welfare, well-being programs** and smart working for employees
- Support **community** and healthcare organisations

Environmental Protection

- **Fight against climate change**: initiatives to reduce energy consumption and emissions in own operations (Scopes 1 & 2), renewable electricity purchased, emissions offsetting projects
- **Circular economy** and **waste reduction** initiatives

Responsible Sourcing

- **Supply chain management** and monitoring plan considering **ESG factors**
- **Supplier awareness** initiatives focused on ESG factors

Ethics and Integrity

- **ESG policies**, processes, management system
- Work against corruption in all its forms, setting the **highest standards of ethical conduct**
- Rigorous adoption of **responsible marketing practices**


ESG objectives are assigned to Group managers as part of the **MBO system**



Recordati Specialty & Primary Care

A history of growth, geographical expansion and business diversification

- Rx and OTC specialty products sold to GPs, hospitals, specialists
- International expansion strategy started in 1999, with direct presence now in 30+ countries across Europe, CEE, CIS and Turkey
- ~8% of revenue from exports to other international markets via licensors
- Diverse set of >100 products (mostly mature, post patent expiry)
- Broad span of therapeutic areas: Cardiovascular, Urology, Gastrointestinal and CNS
- ~1,900 FTEs driving sales through active promotion



■ Subsidiaries and direct selling organizations

■ Countries where Recordati products are sold (under license or export)

Prescription products

ZANIDIP

Zanipress
lisinopril-metoprolol

Eligard®
(leuprolide acetate) for injectable suspension

UROREC®
Silodosin

Livazo®
pitavastatin

REAGILA®
CARIPRAZINE

Seloken®
Metoprolol tartrate

Seloken® ZOK
Metoprolol succinate

Logimax®
Felodipine/metoprolol succinate ER

OTC products

Procto-Glyvenol

TransAct^{LAT}

HEXASPRAY

Casenlax

Lacdigest®

GINKOR
FORT

alodont®

Reuflor®
Lactobacillus reuteri

Magnesio
Supremo®


*Revenue and EBITDA percentages are those in FY 2020

RECORDATI

Recordati Rare Diseases

A global presence, Focused on the Few

- A portfolio of Orphan and Ultra-Orphan products sold to hospitals and specialists
- Primary focus on Metabolic and Endocrine diseases
- Global footprint with access to North America, EU, Japan, Australia/NZ and LatAm
- Plans in place for further geographic expansion (China and other)
- Driving growth through patient and clinician awareness
- Early stage pipeline of proprietary products



- Subsidiaries and direct presence of orphan drug representatives
- Commercial agreements and direct delivery

Endocrinology products

Signifor[®]
pasireotide

Signifor[®] LAR

Isturisa[®]
(osilodrostat)

Metabolic and other products

Carbaglu[®]
carglumic acid

PANHEMATIN[®]
(HEMIN FOR INJECTION)

Cystadrops[®]
Cysteamine hydrochloride

CYSTADANE[®]
betaine anhydrous

Cystagon[®]
Cysteamine bitartrate


Juxtapid[®]
(lomitapide) capsules

LEDAGA[®]
chlormethine

*Revenue and EBITDA percentages are those in FY 2020

Rare Diseases – growing segment with significant unmet need

\$235bn market by 2025 exhibiting strong growth rates



Supported by growing diagnosis rates and new treatments

- Development of new technologies allowing new treatments for previously untreated disease states
- Enhancement of screening methodologies
- Increasing doctor education
- Increasing disease awareness campaigns
- Diagnosis typically at a young age leading to long term 'patients for life'

With significant headroom and market potential

7,000+

More than 7,000 designated rare diseases...

~85%

...of which are 85% serious / life threatening...

500

...with only approximately 500 approved drugs to date

Benefiting from supportive legislation for rare diseases

- | | |
|--|--|
| Market exclusivity with limited competition | <ul style="list-style-type: none">• Development exclusivity due to rare diseases drugs designations• Marketing exclusivity of 7-10 years upon market approval |
| Expedited development pathway | <ul style="list-style-type: none">• Shorter time frame to launch vs. standard drugs• ~11 months for FDA approval (vs. ~17 for standard drugs) |
| Legal and financial benefits | <ul style="list-style-type: none">• Fee waivers, grants, lower cost trials with limited patient population |

R&D - Current pipeline

Speciality and Primary Care

- Main focus on life-cycle management and indication expansions

- New device development

for Eligard®

(leuporelin acetate)



- Support approval and launch of ARS-1, an epinephrine nasal spray for the emergency treatment of allergic reactions, including anaphylaxis.

- Development of pediatric indication for Reagila® (cariprazine), in cooperation with Gedeon Richter.
- Probiotics (*Lactobacillus salivarius* V4II-90) in development as food supplement for the prevention of bacterial infections

Treatments for Rare Disease

- Focus on identifying and adding potential new pipeline assets, and progressing internal pipeline

- Potential extension of indication for US for

Isturisa® (osilodrostat) to the

treatment of patients with

Cushing's syndrome in the US, aim to


discuss plan with FD in early 2022

- Progress current clinical stage projects:

- Development of a treatment for neurotrophic keratitis in collaboration with Mimetech, a company founded by scientists associated with the University of Florence
- Development of a treatment for acute decompensation episodes in MSUD in collaboration with AP-HP (Paris)



M&A and Business Development – an integral part of the Recordati history



Group BD strategy and focus areas

Specialty & Primary Care

Licensing

- New products licensing opportunities in Europe to be pursued in specialty care
- Preferably commercial or late stage / near to market opportunities
- Seen as partner of choice, gaining access to attractive patented products or post LoE products with turn-around growth prospects through active promotion
- Leverage extensive distribution platform and geographical reach

Acquisitions

- Focus on European opportunities (companies and products) in the SPC space where material synergies can be found
- Carve out products with turn-around growth prospects through active promotion
- Selective acquisition of existing well-known OTC brands in multiple or single territories
- Strong integration capabilities within Recordati
- Leverage extensive distribution platform and geographical reach

Group BD strategy and focus areas

Treatments for Rare Diseases

Licensing

- Worldwide or regional licenses of development products , preferably late stage opportunities
- Partnerships with research institutions and other rare disease companies
- Seen as partner of choice due to high level of expertise and international infrastructure
- Leverage worldwide geographical reach

Acquisitions

- Acquisition of rare disease innovative companies or assets on a worldwide or regional basis
- Focus on developing existing therapeutic areas, with synergies potential
- Remain opportunistic in considering new therapeutic areas, leveraging on strong rare disease competences
- Scouting of commercial assets opportunities with growth potential

First nine months 2021 highlights

- Q3 results continued to reflect the positive trends already seen in Q2, with rebound of revenue across SPC, strong contribution from Eligard⁽¹⁾ (all key markets now selling directly) and continued strong growth of Rare Diseases
- YTD Q3 net revenue of €1,156.2 million was +5.7% vs PY or +8.6% at CER; excluding Eligard[®] revenue of €59.4 million, growth in CER would be +3.2%, with good revenue momentum in recent months more than off-setting the full year impact of 2020 LOEs and impact of Covid-19 restrictions particularly on flu medicines in 1H
- Financial results are in line with expectations, with operating results reflecting planned increased investment behind Endo and Eligard[®] and return to higher level of activity in the field. Results also reflect higher financial charges (due to FX volatility) and non-recurring tax benefits of €26.2 million recognized in Q2:
 - EBITDA⁽²⁾ €447.9 million or 38.7% of sales, +2.1%
 - Net Income €296.4 million or 25.6% of sales, +8.1%
 - Adjusted Net Income⁽³⁾ €313.4 million or 27.1% of sales, -1.3%
 - Free cash flow⁽⁴⁾ €352.9 million, an increase of € 69.6 million vs same period 2020
- Continued focus on ESG agenda results in MSCI rating improvement and inclusion in Euronext MIB ESG index
- Board approved interim 2021 dividend of € 0.53 per share, consistent with our dividend policy
- Approved a share buy-back program for a maximum of 1 million shares to service the stock option plans

(1) Acquired under license from Tolmar International Ltd. in January 2021


(2) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items

(3) Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, and non-recurring items, net of tax effects

(4) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options

Eligard® transition ahead of plan, with positive early signals from active promotion

- Revenue of €59.4 million* is ahead of expectations due to earlier switch to direct sales and Recordati promotion in several markets
- Recordati is MA Holder in all Mutual Recognition Procedure markets, with around 30 Marketing Authorisation Transfers completed before the end of September
- Eligard® is being promoted directly by our affiliates in 24 countries and indirectly by our partners in 6 additional countries with positive feedback from HCPs
- Encouraging signs of changes in the sales trend in early promotion markets with August in-market sales returning to growth in Spain and Germany and improvements in other markets including France and Italy
- The development of the new device by Tolmar is progressing, regulatory filing now expected in Q1 2022
- On track to deliver just over €80 million revenue for FY 2021



- Countries directly promoting Eligard®
- Countries indirectly promoting Eligard® by our partners

Signifor® & Signifor LAR® sales growth continues in Q3 2021

Isturisa® launch on track in US, EU and JP

Signifor® and Signifor® LAR commercialization on track



- YTD Q3 2021 reported Net Revenue of ~€58.5 million
- Growth of in-market sales at constant exchange rate estimated to be around 10% vs 2020*
- Continued new patient acquisition in all Regions across all approved indications
- Transfer of Marketing Authorization almost finalized in wave 2 markets

Isturisa® launch and new patient acquisition progressing as planned



- Isturisa® YTD Q3 2021 Net Revenue ~€32 million
- Robust patient uptake in US, France and other EU markets
- Reimbursement price agreed in Germany in line with expectation, discussion ongoing in other EU markets
- Launched in Japan on June 30th, 2021. Performing according to plan
- Strong support from top KOLs and patient organizations continues
- Isturisa expected to achieve peak year sales estimate of between € 300 and 350 million, with potential further upside from expansion of indication to Cushing Syndrome in US and expansion in new territories

* Recordati books only margins on sales of Signifor® and Signifor LAR® until transfer of market authorizations and distribution from Novartis; in market sales performance estimated through net margin gross up for like for like comparison

Main products sales


(million Euro)	9M 2021	9M 2020	Change %
Zanidip® (lercanidipine)	107.2	106.1	1.0
Seloken®/Seloken® ZOK/Logimax® (metoprolol/metoprolol+felodipine)	73.0	77.7	(6.1)
Eligard® ⁽¹⁾	59.4	-	n.m.
Urorec® (silodosin)	45.3	58.5	(22.6)
Livazo® (pitavastatin)	31.8	42.5	(25.0)
Zanipress® (lercanidipine+enalapril)	31.3	38.2	(18.1)
Other corporate products ⁽²⁾	198.1	198.7	(0.3)
Drugs for rare diseases	279.4	232.4	20.2
of which Endo franchise ⁽³⁾	90.5	53.8	68.2

(1) Eligard® net revenue includes margins booked as net revenue until transfer of market authorizations and distribution

(2) Includes the OTC corporate products for an amount of € 79.3 million in 2021 and € 78.4 million in 2020

(3) Endo franchise net revenue 2020 includes margins on sales of Signifor® and Signifor® LAR until transfer of market authorizations

A diversified product portfolio




Data: **First nine months 2021**
Total revenue € **1,156.2 m**

Composition of revenue by geography

(million Euro)	9M 2021	9M 2020	Change %
Italy	195.8	202.9	(3.5)
France	112.2	109.1	2.8
Germany	111.7	100.6	11.1
Spain	85.9	63.1	36.1
Portugal	33.5	32.6	2.8
Turkey	53.5	62.4	(14.3)
Russia, other CIS countries and Ukraine	63.4	69.1	(8.2)
U.S.A.	127.5	89.4	42.6
Other CEE countries	80.3	67.1	19.6
Other W. Europe countries	75.9	66.9	13.5
North Africa	27.3	33.4	(18.1)
Other international sales	153.7	159.3	(3.5)
TOTAL PHARMACEUTICALS	1,120.8	1,055.9	6.1
CHEMICALS	35.4	37.9	(6.6)

(In local currency, millions)	9M 2021	9M 2020	Change %
Russia (RUB) ⁽¹⁾	4,040.3	4,276.8	(5.5)
Turkey (TRY)	478.7	450.3	6.3
U.S.A. (USD)	152.5	100.6	51.6

Geographical breakdown of pharmaceutical¹ revenue



Data: **First nine months 2021**

Pharmaceutical ⁽¹⁾ revenue € **1,120.8 m**

(1) Excluding sales of pharmaceutical chemicals which are € 35.4 million, down by 6.6% and represent 3.1% of total revenue.

(2) Sales to licensees, exports, sales in ROW

First nine months 2021 results

(million Euro)	9M 2021	9M 2020	Change %
Revenue	1,156.2	1,093.8	5.7
Gross Profit	843.2	785.6	7.3
as % of revenue	72.9	71.8	
SG&A Expenses	347.1	310.3	11.8
as % of revenue	30.0	28.4	
R&D Expenses	119.7	106.3	12.6
as % of revenue	10.4	9.7	
Other Income (Expense), net	(3.5)	(4.9)	(27.9)
as % of revenue	(0.3)	(0.4)	
Operating Income	372.9	364.0	2.4
as % of revenue	32.3	33.3	
Financial income/(expenses), net	22.2	11.2	98.3
as % of revenue	1.9	1.0	
Net Income	296.4	274.1	8.1
as % of revenue	25.6	25.1	
Adjusted Net Income ⁽¹⁾	313.4	317.5	(1.3)
as % of revenue	27.1	29.0	
EBITDA ⁽²⁾	447.9	438.8	2.1
as % of revenue	38.7	40.1	

(1) Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, and non-recurring items, net of tax effects


(2) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items

First nine months 2021 results

Operating Segments

REVENUE

Treatments for rare diseases 24.2%



Primary and specialty care 75.8%


Margin on Sales:

Treatments for rare diseases: EBITDA 47.4%, EBIT 38.5%

Specialty & primary care: EBITDA 36.0%, EBIT 30.3%

EBIT


Treatments for rare diseases 28.8%



Primary and specialty care 71.2%

EBITDA

Treatments for rare diseases 29.5%



Primary and specialty care 70.5%

First nine months 2021 cash flow

(million Euro)	9M 2021	9M 2020	Change
EBITDA	447.9	438.8	9.1
Movements in working capital	12.8	(68.8)	81.6
Changes in other assets & liabilities	(14.6)	(18.9)	4.3
Interest received/(paid)	(11.3)	(11.2)	(0.1)
Income Tax Paid	(61.6)	(45.0)	(16.6)
Other	(5.1)	1.6	(6.7)
Cash flow from Operating activities	368.1	296.5	71.6
Capex (net of disposals)	(15.2)	(13.2)	(2.0)
Free cash flow	352.9	283.3	69.6
Increase in intangible assets (net of disposals)	(61.4)	(93.1)	31.7
Dividends paid	(109.4)	(110.5)	1.1
Purchase of treasury shares (net of proceeds)	(29.0)	(15.6)	(13.4)
Other financing cash flows ⁽¹⁾	0.6	25.6	(25.0)
Change in cash and cash equivalents	153.7	89.7	64.0

Net financial position

(million Euro)	30 SEPT 2021	31 DEC 2020	Change
Cash and cash equivalents	341.9	188.2	153.7
Short-term debts to banks and other lenders	(13.5)	(12.6)	(0.9)
Loans and leases – due within one year	(228.1)	(270.2)	42.1
Loans and leases – due after one year ⁽¹⁾	(815.0)	(771.2)	(43.8)
NET FINANCIAL POSITION	(714.7)	(865.8)	151.1

(1) Includes the fair value measurement of the relative currency risk hedging instruments (cash flow hedge)

Full year 2021 outlook

*Expect FY results in line with the objectives set at the start of the year,
at lower end of the guidance range*

- **Revenue likely to land in lower end of target range:**
 - FX headwind of -2%/-3%, slightly adverse to plan (particularly TRY)
 - SPC returning to growth, with first signs of recovery of C&C market unlikely to fully off-set adverse impact in the first part of the year and market headwinds in CEE & Turkey, assuming no significant new waves of Covid restrictions
 - Eligard® transition ahead of schedule (revenue of just over €80 million*)
 - Robust growth of RRD portfolio across all Regions; Endo uptake on track, with base set for further growth in 2022
- **EBITDA margin on track**, 2H reflects increase in field activity and seasonality
- **Financing costs of around €28 million** (reflecting €6-7 million FX losses due to high volatility)
- **Tax rate to be around 17%**, reflecting planned ACE benefit from reverse merger and additional Q2 non-recurring benefit of €13 million from Magnesio Supremo® step up

Financial projections - 3Y Plan presented in May 2021

2021 targets and plan for 2023

(million Euro)	2020 Actual	2021 Targets	2023 Plan Including M&A	CAGR 2020-2023
Revenue	1,448.9	1,570 - 1,620	1,900 - 2,000	10.4%
EBITDA ⁽¹⁾ margin on sales	569.3 39.3%	600 - 620	720 - 760 ±38%	9.1%
Adjusted Net Income ⁽²⁾ margin on sales	410.4 28.3%	420 - 440	530 - 560 ±28%	9.9%

(1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items

(2) Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, and non-recurring items, net of tax effects

CAGR % calculation based on midpoint of the target range

Financial projections - 3Y Plan presented in May 2021

Diversified business with strong organic growth

Strong underlying volume growth over the period in both business segments

S&PC *
CAGR 20-23
+6%

RRD
CAGR 20-23
+15%

High level of profitability

Maintain robust operating and bottom line margin as % of revenue

EBITDA
±38%

Adj. Net
Income
± 28%

Solid cash flow generation

Free Cash Flow conversion

> 100% net income

Clear capital allocation policy

60%

dividend payout at 60% of Net Income

40%

accretive & growth bolt-on M&A and Business Development

Robust Balance Sheet

Retain leverage ratio at

1.5x-1.8x
Net Debt/
EBITDA

depending on timing and structure of deals (with max of close to 3.0x for high quality opportunity)

The Recordati share

The Recordati share (ticker REC, Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271) has been listed on the Italian Stock Exchange since 1984. It belongs to the FTSE MIB, the FTSE IT Health Care, the FTSE4Good Index Series, the MIB ESG and the STOXX Europe 600, EURO STOXX Health Care, MSCI indexes.

Share capital consists of 209,125,156 ordinary (common) shares with a par value of € 0.125 each.


2019 EPS (diluted): € 1.764

2020 EPS (diluted): € 1.698

2020 dividend per share: € 1.05

Dividend pay-out ratio: $\pm 60\%$ of group net income

Ownership:



Appendix

Specialty and Primary Care portfolio

Corporate products

ZANIDIP

Corifeo®

LERCADIP

ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine) antihypertensive

Zanipress

ZANEXTRA



LERCAPREL®

LERCARIL®

ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL® (lercanidipine + enalapril) antihypertensive

Eligard®
(leuprolide acetate) for injectable suspension

ELIGARD® (leuprorelin acetate) hormone dependent advanced prostate cancer

UROREC®
Silodosin

UROREC® (silodosin) benign prostatic hyperplasia

Livazo®
pitavastatin

ALIPZA®

LIVAZO®/ALIPZA® (pitavastatin) hypercholesterolaemia

Seloken®
Metoprolol tartrate

Seloken® ZOK
Metoprolol succinate

Betaloc® ZOK
Metoprolol succinate

SELOKEN®/SELOKEN® ZOK/BETALOK® ZOK (metoprolol succinate) angina pectoris, disturbances of cardiac rhythm, hypertension

Logimax®
Felodipine/metoprolol succinate ER

LOGIMAX® (metoprolol succinate + felodipine) antihypertensive

REAGILA®
CARIPRAZINE

REAGILA® (cariprazine) antipsychotic

ТЕРЖИНАН
Tergynan

TERGYNAN® gynecological infections

CitraFleef®

Fosfosoda®

CITRAFLEET® and FOSFOSODA® bowel evacuants

























POLIDEXA®, ISOFRA® and OTOFA® treatment of ear, nose and throat (ENT) infections

Procto-Glyvenol®

PROCTO-GLYVENOL® (tribenoside) haemorrhoids

Specialty and Primary Care portfolio

OTC

    	REUFLOR[®], CASENBIONIC[®], BIORALSUERO[®], REUTERI[®], GASTRUS[®] (lactobacillus reuteri protectis) food supplements
	HEXA LINE OF PRODUCTS (biclotymol) antibacterial for infections of the oral cavity
 	LOMEXIN[®]/FALVIN[®] (fenticonazole) antimycotic
  	CASENLAX[®]/LAXBENE[®] and FLEET ENEMA[®] constipation and bowel cleansing
	TRANSACT[®] LAT (flurbiprofene transdermal patch) anti-inflammatory
 	URISPAS[®]/GENURIN[®] (flavoxate) urinary tract muscle relaxant
 	RUPAFIN[®]/WYSTAMM[®] (rupatadine) antihistamine
	LOPRESOR[®] (metoprolol) antihypertensive
 	ABUFENE[®] and MUVAGYN[®] symptoms of menopause
	LACDIGEST[®] (tilactase) lactose intolerance
 	VITAROS[®]/VIRIREC[®] (alprostadil) erectile dysfunction
	FORTACIN[®] (lidocaine+prilocaine) premature ejaculation

Rare Disease portfolio

Endocrinology products



SIGNIFOR® and SIGNIFOR® LAR (pasireotide) Treatment of Cushing's disease and acromegaly



ISTURISA® (osilodrostat) Treatment of Cushing's disease (United States of America) and Cushing's syndrome (European Union, Switzerland)

Metabolic and other products



CARBAGLU® (carglumic acid) Treatment of hyperammonemia due to N-acetylglutamate synthase deficiency (NAGS deficiency) and some organic acidurias (isovaleric aciduria, methylmalonic aciduria and propionic aciduria)



NORMOSANG®/PANHEMATIN® (human hemin) Treatment of acute attacks of hepatic porphyria



CYSTADANE® (betaine anhydrous) Treatment of homocystinuria



CYSTADROPS® (cysteamine hydrochloride) Treatment of the ocular manifestations of cystinosis



COSMEGEN® (dactinomycin for injection) Treatment of rare cancers: Wilms tumour, infantile rhabdomyosarcoma, Ewing sarcoma and metastatic nonseminomatous testicular cancer



JUXTAPID® (lomitapide) Treatment of homozygous familial hypercholesterolemia (HoFH)



CYSTAGON® (cysteamine bitartrate) Treatment of nephropathic cystinosis



LEDAGA® (chlormethine hydrochloride) Treatment of mycosis fungoides (MF), T-cell cutaneous lymphoma (CTCL)



PEDEA®/NEOPROFEN® (IV ibuprofene) Treatment of patent ductus arteriosus (PDA)

Company declarations, disclaimers and profile

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Luigi La Corte declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this presentation corresponds to the document results, books and accounting records.

Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.

All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.

Offices:

Recordati S.p.A.
Via M. Civitali 1
20148 Milano, Italy

Investor Relations:

Federica De Medici
+39 02 48787146
demedici.f@recordati.it

Investor Relations:

Lucia Abbatantuoni
+39 02 48787213
abbatantuoni.l@recordati.it

Website:

www.recordati.com